Bruker is Ushering in the Age of Spatial Single-Cell Metabolomics
Bruker Corporation (Nasdaq: BRKR) revealed significant innovations in spatial multiomics at the 18th International Conference of the Metabolomics Society. Key advancements include Spatial Single-Cell Metabolomics (SSCM) for detailed metabolic tissue characterization and a new microGRID™ technology enhancing the timsTOF® fleX system's capabilities. These tools enable high-resolution metabolic analyses essential for cancer research and drug discovery. Additionally, Bruker launched updated MetaboScape and TASQ software for enhanced metabolomic profiling.
- Introduction of Spatial Single-Cell Metabolomics (SSCM) for enhanced metabolic tissue characterization.
- Launch of microGRID™ technology, improving the timsTOF® fleX system for artifact-free imaging.
- Next-generation MetaboScape and TASQ software enhance metabolomic profiling capabilities.
- None.
- Novel unbiased, in situ Spatial Single-Cell Metabolomics (SSCM) enables high-throughput metabolic tissue characterization with single-cell resolution
- New 5 µm microGRID™ technology for timsTOF® fleX MALDI mode provides virtually artifact-free small-molecule images across large field of view
- Novel 4D-Metabolomics methods use CCS-Predict Pro AI/DL to enrich lipids, metabolite, and glycan libraries with molecular collision cross sections (CCS)
Combining SSCM with the recently announced MALDI HiPLEX-IHC workflow enables in situ single cell immunometabolomics studies that integrate metabolomics-based immune reprogramming with targeted proteomics. This single-cell multiomics workflow is enabled by the new microGRID™ smartbeam™ 3D MALDI source for timsTOF® fleX systems for sub-micron positioning for spatial resolution down to five micrometers (5 µm), virtually eliminating any artifacts in the co-registration of MALDI molecular images with optical microscopy.
Single-cell technologies have revolutionized the understanding of heterogeneous biological processes underlying cancer, regenerative medicine, aging, and liver diseases. Studying cell-to-cell tissue variation enhances translational research, for example, in the development of better cancer research methods for the development of therapeutics targeting rare tumor cells.
Professor
Bruker today also announced the next-generation of its advanced MetaboScape® and TASQ® software for metabolomic profiling and quantitation. MetaboScape 2022b now features integration of CCS-Predict Pro machine learning. Accurate and reproducible CCS values measured on the timsTOF platform can be matched to CCS values predicted from compound libraries or biotransformation algorithms, adding an orthogonal dimension for confident compound annotation.
TASQ 2022b complements the established target screening and quantitation functionality by a CCS-enabled isotope tracing workflow module. Data processing for large scale stable isotope tracer experiments is simplified as key algorithms such as the correction for naturally occurring isotopes and fractional contribution of isotopic labels are provided.
About
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005515/en/
Media
T: +49 (421) 2205-2843
E: petra.scheffer@bruker.com
Investor Relations
Sr. Director Investor Relations &
T: +1 (978) 663–3660, ext. 1479
E: Investor.Relations@bruker.com
Source:
FAQ
What innovations did Bruker announce regarding SSCM?
How does the new microGRID™ technology benefit Bruker's imaging systems?
What are the key features of the updated MetaboScape and TASQ software?